Retrospective cohort study finds omalizumab treatment increases alopecia areata risk in asthma and CSU patients, indicating potential side effects.
The data that support the findings of this study are available from TriNetX. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from https://trinetx.com/ with the permission of TriNetX. Table S1: Omalizumab indication and co-variate medical billing code definitions. Table S2: Risk of alopecia areata (AA) and alopecia totalis (AT) or alopecia universalis (AU) development in omalizumab-treated asthma and chronic spontaneous urticaria (CSU) patients. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Thang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: